04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
18:21 , May 25, 2018 |  BC Week In Review  |  Company News

Antengene adds bundle of Karyopharm assets to pipeline

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
22:16 , May 24, 2018 |  BC Extra  |  Company News

Antengene fills pipeline with Karyopharm deal

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
23:14 , Mar 20, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays CRISPR-based screening in human cells could help identify the therapeutic targets of small molecules. The method involved three steps: generating in-frame mutations in human cell lines by engineering them to express CRISPR-associated...
19:10 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Colitis Patient sample and mouse studies suggest inhibiting PAK1 and PAK2 could help treat colitis. In samples from patients with inflammatory bowel disease (IBD), levels of a PAK1-induced gene signature were higher in inflamed...
19:51 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample, cell culture and mouse studies suggest inhibiting PAK1 or PAK4 could help treat drug-resistant BRAF-mutant melanoma. In tumor samples from metastatic melanoma patients, high primary tumor levels of PAK1 were associated...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Yes-associated protein 1 (YAP1; YAP); p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1)

Hepatic disease INDICATION: Liver fibrosis Cell culture and mouse studies suggest inhibiting YAP1 or PAK1 could help treat liver fibrosis. In activated rat primary liver myofibroblasts, the YAP1 inhibitor Visudyne verteporfin or a PAK1 inhibitor...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

KPT-9274: Phase I started

Karyopharm began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate oral KPT-9274 with or without extended-release niacin given 3 times a week every other day of a 28-day cycle in about 175 patients....
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Cancer Research UK, Pangaea Biotech deal

Pangaea and Cancer Research UK’s commercialization and development arm, Cancer Research Technology (CRT), partnered to develop CRT’s p21 protein (Cdc42 Rac)-activated kinase (PAK) inhibitors for cancer. Both partners will be responsible for lead optimization, and...
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Neurofibromatosis p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1) In vitro and mouse studies identified PAK1 inhibitors that could help treat neurofibromatosis type 2 (NF2). PAK1...